Caribou Biosciences, Inc. will host a webcast on November 3, 2025, to present new data from the ANTLER phase 1 clinical trial of vispacabtagene regedleucel for patients with r/r B-NHL and CB-011 for r/r multiple myeloma. Vispa-cel is the first allogeneic CAR-T cell therapy with a PD-1 knockout, while CB-011 is engineered with a B2M–HLA-E fusion protein to prevent immune rejection. Both therapies have received Fast Track and Orphan Drug designations from the FDA. Caribou is dedicated to developing precision cell therapies for hematologic malignancies. For more information, visit their website.

Read more at GlobeNewswire: Caribou Biosciences to Host Webcast to Report New Data